Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Sage Therapeutic Com (NQ: SAGE)
152.08 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:39 PM EDT, Aug 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 152.08
Bid (Size) 148.75 (1)
Ask (Size) 153.50 (2)
Prev. Close 152.08
Today's Range 152.08 - 152.08
52wk Range 59.57 - 195.97
Shares Outstanding 46,515,858
Dividend Yield N/A
Performance
YTD
-8.75%
-8.75%
1 Month
-9.78%
-9.78%
3 Month
-6.75%
-6.75%
6 Month
-6.80%
-6.80%
1 Year
+89.08%
+89.08%
Top News
More News
Karuna Appoints Seasoned Biopharma Veteran Steven Paul, M.D., as Chief Executive Officer
Karuna Appoints Steven Paul, M.D., As Chief Executive Officer Read More
from Business Wire News Releases
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business... Read More
from Business Wire News Releases
More News
Read More
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from Business Wire News Releases
Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference
from Business Wire News Releases
How We’re Working to Meet the Needs of People Living and Aging With HIV
category Gilead , NYSE:GILD , HTW Campaign , and 14 more.
from 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
from Business Wire News Releases
SAGE: Ensuring Dignity and Respect for LGBT Elders
category Reduced Inequalities , LGBTQ , Diversity & Inclusion , and 6 more.
from 3BL Media: Corporate Social Responsibility, Energy and Health News
Analysts Anticipate 10% Upside For The Holdings of IWR
category ETFs
from ETF Channel
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
from PR Newswire
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from Business Wire News Releases
A pharma CEO says a new depression drug could have lasting effects after one short course, like antibiotics — here's what experts think (SAGE)
category Health, Sage Therapeutics, Drugs, Depression, Pharmaceutical Industry, Pharmaceuticals, Brain, Neuro
from Business Insider
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.